Why BlueWind Medical’s $47.8m raise matters for the next phase of UUI treatment
UUI devices have clinical momentum. BlueWind Medical’s next challenge is proving Revi can scale through access, reimbursement, and workflow adoption.
Why BlueWind Medical’s latest FDA clearance matters for long-term urgency urinary incontinence care
BlueWind Medical secures FDA clearance for an enhanced Revi wearable. Find out why usability may define the next phase of neuromodulation adoption.